The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

This past week, according to the Associated Press, the agreement was announced by Illinois-based Abbott Laboratories to pay $1.5 billion in criminal fines, civil settlements and forfeiture. Abbott pled guilty to promoting the anti-seizure medication, Depakote, for uses which had not been approved by the U.S. Food and Drug Administration (FDA). The Washington Post article by N.C. Aizenman of May 7, 2012, announced the settlement as $1.6 billion.[1] According to Aizenman, this is “the second-largest in a string of multimillion-dollar payouts in recent years.” (Pfizer’s $2.3 billion settlement in 2009 is so far, the largest.)[2] Whatever the dollar amount beyond a billion, Deputy Attorney General James Cole noted that this settlement represented efforts by the U.S. Government “to hold accountable those who commit fraud.”[3] Abbott said they’re pleased the matter is resolved.

The company’s strategy, according to the Associated Press’ syndicated column of May 8, 2012, in The Daily News Record, was at fault; and it was a top-down strategy involving high-level executives who sanctioned and promoted the aggressive marketing of Depakote for uses for which it had not been approved, including to treat schizophrenia, agitated dementia and autism.

Abbott admitted having trained its sales force to sell Depakote to treat dementia, to sedate patients in nursing home settings, because the drug did not come under the umbrella of federal regulations which would have prevented “the use of unnecessary medications”[4] in nursing homes. While a physician can prescribe a drug generally designated for a different purpose, a company cannot market a drug for a purpose for which it has not been approved by the FDA.

Whistleblowers brought Abbott’s practices to the attention of federal investigators. Abbott Labs says, “It takes its responsibility to patients and health care providers seriously.”[5] It is our opinion, at that price tag it should do so.

[1] Abbott Labs Agrees To Pay $1.6 Billion Over Illegal Marketing of Depakote, Aizenman, N.C., The Washington Post, May 7, 2012,

[2] Op.Cit.

[3] “Abbott Labs Agrees To Pay $1.5 Billion Settlement”, Associated Press, May 8, 2012, The Daily News Record, Harrisonburg, Va.

[4] Op. Cit.

[5] Ibid.


  1. Gravatar for Daniel Haszard

    Reg-Abbott labs off-label promotion of Depakote.

    I took Depakote for 6 years was ineffective for my condition PTSD,the doctor kept telling me to take it.

    The saga of the schizophrenia drugs is one of incredible profit.Eli Lilly made $65 BILLION on Zyprexa franchise. Described as *the most successful drug in the history of neuroscience*.There is a whole underclass block of our society,including children in foster care that are the market for these drugs,but have little voice of protest if harmed by them.

    --Daniel Haszard

    *tell the truth don't be afraid*

  2. Gravatar for Greg Webb

    Mr. Haszard,

    You are correct, in my opinion. One has to rely on his/her physician to get it right, but if the physician is getting bad information from the manufacturer, then the problem is compounded many times. I hope you are doing well now. Thanks for commenting.

    Greg Webb

Comments are closed.

Of Interest